Clinical trial · no report yet · Phase 1/Phase 2
AMPLIFY-7P
A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors
- NCT05726864 ↗
- Active, not recruiting
- Elicio Therapeutics
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 8 | |
| YouTube | 2 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- First in Human Phase 1/2 Trial of ELI-002 7P Immunotherapy as Treatment for Subjects With Kirsten Rat Sarcoma (KRAS)/Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors
- Phase
- Phase 1/Phase 2
- Status
- Active, not recruiting
- Conditions
- Pancreatic Ductal Adenocarcinoma; Colorectal Cancer; KRAS G12D; KRAS G12R; KRAS G12V; KRAS G12A; KRAS G12C; KRAS G12S; KRAS G13D; NRAS G12D; NRAS G12R; NRAS G12V; NRAS G12C; NRAS G12S
- Interventions
- ELI-002 7P
- Arms
- Phase 1A: ELI-002 7P (Low Peptide dose) · Experimental
- Phase 1A: ELI-002 7P (High Peptide dose) · Experimental
- Phase 1B: ELI-002 7P · Experimental
- Phase 2 randomized: ELI-002 7P · Experimental
- Enrollment
- 158
- Primary outcomes
- Phase 1: Evaluate the safety of ELI-002 7P
- Phase 2: Compare ELI-002 7P versus standard of care (SOC; observation) in DFS (disease free survival)
- Sponsor
- Elicio Therapeutics
- Start
- Apr 14, 2023
- Primary completion
- Apr 20, 2026
- Results posted
- No
- Registry record
- NCT05726864 · updated Jul 10, 2026